Advertisement
Screener

REZOLUTE, INC. (RZLT) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

1.6 / 5 stars · 18/56 Roast Me

REZOLUTE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

REZOLUTE, INC. (RZLT) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 84.00% for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-24.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-09-24

  • REZOLUTE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-09-30 was 83.00%.
  • REZOLUTE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2019-09-30 was 118.00%.
  • REZOLUTE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2016-09-30 was 74.00%, a 26.00% decline year-over-year.
  • REZOLUTE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2015-09-30 was 100.00%.
  • REZOLUTE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2026 was 84.00%, a 0.00% change from fiscal 2025.
  • REZOLUTE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 84.00%, a 15.15% decline from fiscal 2024.
  • REZOLUTE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 99.00%, a 8.79% increase from fiscal 2023.
  • REZOLUTE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 91.00%, a 3.19% decline from fiscal 2022.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 1 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month
2026-06-3084.00%
10-K · filed 2026-09-24
2026-03-3184.00%
10-Q · filed 2026-05-12
2025-12-3184.00%
10-Q · filed 2026-02-12
2025-09-3083.00%
10-Q · filed 2025-11-06
2025-06-3084.00%
10-K · filed 2026-09-24
2024-06-3099.00%
10-K · filed 2025-09-17
2023-06-3091.00%
10-K · filed 2024-09-19
2022-06-3094.00%
10-K · filed 2023-09-14
2021-06-30118.00%
10-K · filed 2022-09-15
2020-03-31118.00%
10-Q · filed 2020-05-14
2019-12-31118.00%
10-Q · filed 2020-02-12
2019-11-30119.00%
10-Q · filed 2020-05-14
2019-09-30118.00%
10-Q · filed 2019-11-14
2018-03-3184.00%
10-Q · filed 2018-05-15
2017-12-3184.00%
10-Q · filed 2018-02-14
2016-09-3074.00%
10-Q · filed 2016-11-14
2016-03-31100.00%
10-Q · filed 2016-05-16
2015-12-31100.00%
10-Q · filed 2016-02-16
2015-09-30100.00%
10-Q · filed 2015-11-16
2014-06-3094.00%
10-K · filed 2014-09-30
2013-03-31111.00%
10-Q · filed 2013-05-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Turn Therapeutics Inc. (TTRX)United States$0.397B-25.68
GALECTIN THERAPEUTICS INC (GALT)United States$0.399B-11.06
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
Opus Genetics, Inc. (IRD)United States$0.406B-3.16
RELMADA THERAPEUTICS, INC. (RLMD)United States$0.406B-11.92
Vogenx, Inc. (VOGX)United States$0.355B
ARS Pharmaceuticals, Inc. (SPRY)United States$0.414B-3.70
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
ENANTA PHARMACEUTICALS INC (ENTA)United States$0.349B-6.72
Emergent BioSolutions Inc. (EBS)United States$0.347B-2.43